[New anticoagulants].
The quest to develop new antithrombotic agents has been stimulated by clinical needs and by advances in biotechnology that have made it possible to produce drugs that target specific steps in thrombogenesis. Established anticoagulants such as unfractionated heparin and the coumarins are effective, but have two major limitations: narrow therapeutic windows and highly unpredictable dose-response relationships. Consequently, these drugs often cause complications such as serious bleeding that require close monitoring of their use by laboratory tests to balance safety and effect. These limitations provided the impetus for the development of new anticoagulants that inactivate thrombin, factor Xa, factor IXa or the factor VIIa/tissue factor complex. Similarly, agents that enhance the protein C anticoagulant pathway have also been developed. Of these, direct thrombin inhibitors, soluble thrombomodulin, protein C, and activated protein C have been evaluated clinically for parenteral administration. However, there is enormous interest in the development of safer and more effective oral anticoagulants. In the future, such orally active direct inhibitors of thrombin and factor Xa, if they can be given safely without the need for laboratory monitoring, may replace the coumarins for the long-term treatment of thromboembolic disorders. To achieve these goals, these compounds need high, consistent oral bioavailability.
Kawasaki
T
T
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki 305-8585, Japan. kawasat@yamanouchi.co.jp
Hirayama
F
F
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D001682:Biological Availability; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors*; D006801:Humans; D011486:Protein C; D018180:Thrombomodulin; D013927:Thrombosis / Q000188:drug therapy
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D011486:Protein C; D018180:Thrombomodulin